What's new in soft tissue and bone pathology 2022-updates from the WHO classification 5th edition

Area of Science:

• Oncology
• Pathology
• Genetics

Background:

• The World Health Organization (WHO) Classification of Soft Tissue and Bone Tumors is a critical resource for diagnosis and treatment.
• The 5th edition, released in 2020, reflects recent advancements in understanding tumor biology and classification.

Purpose of the Study:

• To summarize the major revisions and updates introduced in the 5th edition of the WHO Classification of Soft Tissue and Bone Tumors.
• To highlight key changes in tumor classification, risk stratification, and the recognition of novel entities.

Main Methods:

• Review of the 2020 WHO Classification of Soft Tissue and Bone Tumors (5th edition).
• Identification and description of significant reclassifications and newly recognized disease processes.
• Emphasis on the role of molecular findings, such as recurrent gene fusions, in driving these changes.

Main Results:

• Several soft tissue and bone tumor entities have been reclassified based on new scientific evidence.
• The classification incorporates novel disease processes, particularly those characterized by specific recurrent gene fusions.
• Refinements have been made to risk classification systems for various tumor types.

Conclusions:

• The 5th edition of the WHO Classification represents a substantial evolution in the understanding and categorization of soft tissue and bone tumors.
• These updates are crucial for accurate diagnosis, prognostication, and guiding therapeutic strategies.
• The integration of molecular data, especially gene fusions, is transforming the field of tumor classification.